Study on the antinociceptive action of Tyr-K-MIF-1, a peptide from the MIF family

Related Experiment Video

Updated: Jul 16, 2026

Intracerebroventricular Treatment with Resiniferatoxin and Pain Tests in Mice
06:04

Intracerebroventricular Treatment with Resiniferatoxin and Pain Tests in Mice

Published on: September 2, 2020

R Zamfirova1, A Bocheva, Y Dobrinova

  • 1Institute of Physiology, Bulgarian Academy of Sciences, 1113 Sofia, Bulgaria.

Autonomic & Autacoid Pharmacology
|March 30, 2007
PubMed

Insights

The neuropeptide Tyr-K-MIF-1 produces short-lasting analgesia in rats, which is blocked by naloxone. This pain relief involves the histaminergic system, as histamine receptor antagonists and agonists affect Tyr-K-MIF-1

Area of Science:

  • Neuroscience
  • Pharmacology
  • Pain research

Background:

  • Tyr-K-MIF-1 is a neuropeptide with low affinity for opiate mu-receptors, unlike other melanocyte inhibiting factors (MIFs).
  • Other MIFs, such as Tyr-MIF-1 and Tyr-W-MIF-1, primarily induce antinociception via opioid receptor activation.
  • The specific mechanism of Tyr-K-MIF-1's antinociceptive effect, particularly the involvement of the histaminergic system, remains to be fully elucidated.

Purpose of the Study:

  • To investigate the antinociceptive potential of the neuropeptide Tyr-K-MIF-1 in a rat model.
  • To determine the role of the histaminergic system in the mechanism underlying Tyr-K-MIF-1-induced antinociception.

Main Methods:

  • Antinociceptive effects of Tyr-K-MIF-1 were assessed in rats using the paw-pressure test.
  • The influence of naloxone, a mu-opioid receptor antagonist, on Tyr-K-MIF-1's effect was evaluated.
  • The involvement of histamine receptors (H1, H2, H3) was examined using specific antagonists and agonists administered before Tyr-K-MIF-1.

Main Results:

  • Tyr-K-MIF-1 administration resulted in short-lasting analgesia, which was reversed by naloxone.
  • Antagonists for H1 (diphenhydramine) and H2 (famotidine) histamine receptors significantly reduced Tyr-K-MIF-1's antinociceptive effect.
  • Combined H1/H2 blockade, H2 agonist (dimaprit), and H3 agonist (R-(alpha)-methylhistamine) abolished Tyr-K-MIF-1-induced analgesia.

Conclusions:

  • Tyr-K-MIF-1 exhibits antinociceptive properties in rats, partially mediated by opioid receptors.
  • The histaminergic system plays a crucial role in mediating Tyr-K-MIF-1's analgesic effects.
  • These findings suggest a complex interaction between neuropeptide signaling and histamine pathways in pain modulation.

More Related Videos

A Modified Inflammatory Pain Model to Study the Analgesic Effect in Mice06:54

A Modified Inflammatory Pain Model to Study the Analgesic Effect in Mice

Published on: November 15, 2024

Establishing a Mouse Model of a Pure Small Fiber Neuropathy with the Ultrapotent Agonist of Transient Receptor Potential Vanilloid Type 109:39

Establishing a Mouse Model of a Pure Small Fiber Neuropathy with the Ultrapotent Agonist of Transient Receptor Potential Vanilloid Type 1

Published on: February 13, 2018

Related Concept Videos

Analgesia and Pain Management01:25

Analgesia and Pain Management

Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
Opioid Receptors: Overview01:22

Opioid Receptors: Overview

Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2, D-Pen5]-enkephalin or DPDPE for...
Nociception01:44

Nociception

Nociception—the ability to feel pain—is essential for an organism’s survival and overall well-being. Noxious stimuli such as piercing pain from a sharp object, heat from an open flame, or contact with corrosive chemicals are first detected by sensory receptors, called nociceptors, located on nerve endings. Nociceptors express ion channels that convert noxious stimuli into electrical signals. When these signals reach the brain via sensory neurons, they are perceived as pain. Thus, pain helps the...
Opioid Analgesics: Synthetic and Semisynthetic Opioids01:15

Opioid Analgesics: Synthetic and Semisynthetic Opioids

Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...